Literature DB >> 26177862

Concomitant expression of far upstream element (FUSE) binding protein (FBP) interacting repressor (FIR) and its splice variants induce migration and invasion of non-small cell lung cancer (NSCLC) cells.

Benedikt Müller1, Michael Bovet1, Yi Yin2,3, Damian Stichel4, Mona Malz1, Margarita González-Vallinas1, Alistair Middleton4, Volker Ehemann1, Jennifer Schmitt1, Thomas Muley5,6, Michael Meister5,6, Esther Herpel1,7, Stephan Singer1,8, Arne Warth1,6, Peter Schirmacher1, Dirk Drasdo2,3,9, Franziska Matthäus4, Kai Breuhahn1.   

Abstract

Transcription factors integrate a variety of oncogenic input information, facilitate tumour growth and cell dissemination, and therefore represent promising therapeutic target structures. Because over-expression of DNA-interacting far upstream element binding protein (FBP) supports non-small cell lung cancer (NSCLC) migration, we asked whether its repressor, FBP-interacting repressor (FIR) is functionally inactivated and how FIR might affect NSCLC cell biology. Different FIR splice variants were highly expressed in the majority of NSCLCs, with the highest levels in tumours carrying genomic gains of chromosome 8q24.3, which contained the FIR gene locus. Nuclear FIR expression was significantly enriched at the invasion front of primary NSCLCs, but this did not correlate with tumour cell proliferation. FIR accumulation was associated with worse patient survival and tumour recurrence; in addition, FIR over-expression significantly correlated with lymph node metastasis in squamous cell carcinomas (SCCs). In vitro, we applied newly developed methods and modelling approaches for the quantitative and time-resolved description of the pro-migratory and pro-invasive capacities of SCC cells. siRNA-mediated silencing of all FIR variants significantly reduced the speed and directional movement of tumour cells in all phases of migration. Furthermore, sprouting efficiency and single cell invasiveness were diminished following FIR inhibition. Interestingly, the silencing of FIR isoforms lacking exon 2 (FIR(Δexon2)) alone was sufficient to reduce lateral migration and invasion. In summary, by using scale-spanning data derived from primary human tissues, quantitative cellular analyses and mathematical modelling, we have demonstrated that concomitant over-expression of FIR and its splice variants drives NSCLC migration and dissemination.
Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  lung cancer; metastasis; splice variants; transcription factor

Mesh:

Substances:

Year:  2015        PMID: 26177862     DOI: 10.1002/path.4588

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  16 in total

1.  Contrast-enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early-phase non-small cell lung cancer.

Authors:  Ninglu Yuan; Xiaohe Zhang; Yonghui Cao; Xiaojie Jiang; Si Zhao; Yingying Feng; Yimeng Fan; Zhitao Lu; Hongmei Gao
Journal:  Exp Ther Med       Date:  2017-09-19       Impact factor: 2.447

2.  Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways.

Authors:  Daye Zhang; Yongxiang Zhang; Zeyuan Cai; Ying Tu; Zhansong Hu
Journal:  Exp Ther Med       Date:  2019-11-21       Impact factor: 2.447

3.  Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer.

Authors:  Na Li; Lu Han; Hui Jing
Journal:  Exp Ther Med       Date:  2017-08-16       Impact factor: 2.447

Review 4.  The master regulator FUBP1: its emerging role in normal cell function and malignant development.

Authors:  Lydie Debaize; Marie-Bérengère Troadec
Journal:  Cell Mol Life Sci       Date:  2018-10-20       Impact factor: 9.261

5.  Integrated In Silico Analyses Identify PUF60 and SF3A3 as New Spliceosome-Related Breast Cancer RNA-Binding Proteins.

Authors:  Jennyfer M García-Cárdenas; Isaac Armendáriz-Castillo; Andy Pérez-Villa; Alberto Indacochea; Andrea Jácome-Alvarado; Andrés López-Cortés; Santiago Guerrero
Journal:  Biology (Basel)       Date:  2022-03-22

6.  MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer.

Authors:  Woda Shi; Jianxiang Song; Wencai Wang; Yajun Zhang; Shiying Zheng
Journal:  Mol Med Rep       Date:  2017-09-19       Impact factor: 2.952

Review 7.  A narrative review of the migration and invasion features of non-small cell lung cancer cells upon xenobiotic exposure: insights from in vitro studies.

Authors:  Catarina Albuquerque; Rita Manguinhas; João G Costa; Nuno Gil; Jordi Codony-Servat; Matilde Castro; Joana P Miranda; Ana S Fernandes; Rafael Rosell; Nuno G Oliveira
Journal:  Transl Lung Cancer Res       Date:  2021-06

8.  FIR haplodeficiency promotes splicing to pyruvate kinase M2 in mice thymic lymphoma tissues revealed by six-plex tandem mass tag quantitative proteomic analysis.

Authors:  Asako Kimura; Kouichi Kitamura; Guzhanuer Ailiken; Mamoru Satoh; Toshinari Minamoto; Nobuko Tanaka; Fumio Nomura; Kazuyuki Matsushita
Journal:  Oncotarget       Date:  2017-07-07

9.  Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.

Authors:  Sohei Kobayashi; Tyuji Hoshino; Takaki Hiwasa; Mamoru Satoh; Bahityar Rahmutulla; Sachio Tsuchida; Yuji Komukai; Tomoaki Tanaka; Hisahiro Matsubara; Hideaki Shimada; Fumio Nomura; Kazuyuki Matsushita
Journal:  Oncotarget       Date:  2016-12-13

10.  Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways.

Authors:  Bin Zhang; Feng Tao; Hao Zhang
Journal:  Mol Med Rep       Date:  2018-02-01       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.